louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01226589: Pharmacist Discharge Medication Reconciliation Study
Official title: The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Medication Reconciliation
Keywords: Cancer cancer
MRS
Treatment response
Histologically confirmed diagnosed Breast cancer.
Patient is 18 years or older.
Karnofsky performance score is equal to or greater than 70.
No previously irradiated or recurrent breast.
No contraindication to MRS/MRI.
Lead sponsor: AHS Cancer Control Alberta
Sponsor class: OTHER
First posted: 2010-10-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Adverse drug events can occur commonly due to medication errors during the transition of care in a health care facility. Medication reconciliation is the process of comparing medications and providing an accurate medication list as a resource for prescribers, which is currently only being done upon inpatient admission at the CCI. The purpose of this study is to see if pharmacist medication reconciliation at discharge reduces unintentional medication discrepancies for inpatient discharges.


Eligibility criteria: Inclusion Criteria:

* Cancer inpatients under the care of Dr. Follett or Dr. Candler
* Cancer inpatients to be discharged from the CCI
* Patients \>18 years of age
* Patients that are taking \>1 medications or herbals total at home.

Exclusion Criteria:

* Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron patients or patients receiving radiation treatment for thyroid)
* Patients that do not remain in hospital \>72 hours
* Patients without a home phone number or equivalent contact number.
* Language barrier (patients unable to speak or understand English).
* Patients that are readmitted and already included into the study.

Primary outcomes:
measure: MRS Correlation with Treatment Response.
timeFrame: up to 1 year
Secondary outcomes:
measure: Correlation with Tumor Stage
timeFrame: up to 1 year
measure: The frequency of each type of unintentional medication discrepancies.
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: Cross Cancer Institute
state: Alberta
Study officials:
affiliation: AHS Cancer Control Alberta
name: Carole Chambers, BSc. Pharmacy
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00037089: A Phase II Study of Paclitaxel, UFT, and Leucovorin in Patients With Metastatic Esophageal Cancer
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Esophageal Neoplasm
Lead sponsor: Edelman, Martin, M.D.
Sponsor class: INDIV
Collaborators: name: Bristol-Myers Squibb
First posted: 2002-05-15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: This study is for patients with esophageal cancer that has spread to other areas. The purpose of this study is to:

1. Determine how well a combination of taxol, UFT, and leucovorin work in these patients,
2. Determine the survival of patients with metastatic esophageal carcinoma treated with this combination of drugs.
3. Identify the side effects of this drug combination.


Eligibility criteria: INCLUSION

* Histologic proof of esophageal cancer
* No more than one prior non-taxane chemotherapy regimen for either treatment of localized disease or metastatic disease AND they may not have received a regimen containing low dose continuous infusion of 5-FU (i.e. \>5 days of infusion/cycle), capecitabine or UFT
* No prior therapy with UFT+/-leucovorin, a taxane, capecitabine, low dose continuous infusion of 5-FU or ethynyl uracil.
* Radiographic or physical examination documentation of metastatic disease
* No major surgery within the 2 weeks preceding the start of treatment and fully recovered from any complications of surgery
* No radiation within 2 weeks of beginning chemotherapy.
* No chemotherapy within 4 weeks of beginning treatment.
* Patients must wait at least 6 weeks after receiving BCNU or Mitomycin-C.
* Minimum life expectancy of 3 months
* Informed consent given
* Laboratory values within limits set by study.

EXCLUSION

* More than one prior chemotherapy regimen for metastatic disease
* Current serious medical or psychiatric illness that would prevent informed consent or intensive treatment
* \>grade 1 peripheral sensory or motor neuropathy
* Pregnant
* Patient is taking the drug Sorivudine

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: University of Maryland Cancer Center
state: Maryland
Study officials:
References:
Clinical trial NCT02136589: Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes
Official title: Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hyperemia
Intraocular Pressure
Lead sponsor: Tokyo University
Sponsor class: OTHER
First posted: 2014-05-13
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: PG-analogues induce hyperemia as one of side effects in addition to IOP reduction.

IOP reduction is caused by direct FP receptor stimulation, but the cause of hyperemia is not clarified.

Because FP receptor stimulation induce intrinsic production of PGs, hyperemia or IOP reduction may be due to secondary induced PGs.

Thus, pretreatment with NSAID may affect the PG-analogue induced hyperemia or IOP reduction.


Eligibility criteria: Inclusion Criteria:

1. normal healthy eye
2. not applicable for IOP level
3. not wearing contact lenses
4. not applicable for the presence of the ocular surface diseases in case the treatment was not needed

Exclusion Criteria:

1. the eyes with chronic or recurrent uveitis, scleritis, corneal herpes infection
2. the eyes with the history of trauma, intraocular surgery, or Laser surgery within 6 months
3. the eyes with difficulty for the measurement of IOP with the applanation tonometer
4. the subjects with the allergy for PG-analogues or benzalkonium chloride
5. the subjects using the eyedrops excluding those in this study
6. the subjects treated with oral carbonic anhydrase inhibitor
7. the subject with Sjogren syndrome
8. the subjects who can not drop periodically
9. the subjects with the advanced glaucoma or the terminal stage of glaucoma
10. the subjects with the severe ocular complications

Primary outcomes:
measure: IOP reduction
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02393989: Three-Year Clinical Evaluation of Bonded Posterior Restorations: Amalgam vs Resin Composite
Official title: Three-Year Clinical Evaluation of Bonded Posterior Restorations: Amalgam vs Resin Composite
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Class II Lesions
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2015-03-20
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background: This 3-year clinical trial compared the performance and post-operative sensitivity of a posterior resin composite with that of bonded-amalgam in large sized cavities. Additionally, it was evaluated whether resin composite could be an alternative for bonded amalgam.

Methods: This was a randomized clinical trial. Patients in need of at least two posterior restorations were recruited. Authors randomly assigned one half of the restorations to receive bonded-amalgam and the other half to composite restorations. Forty bonded-amalgams and composites were evaluated for their performance on modified Ryge criteria and post-operative sensitivity using VAS for 36-months.


Eligibility criteria: Inclusion Criteria:

To be included, the teeth to be restored had to:

1. be asymptomatic
2. have occlusal and adjacent teeth in contact
3. have cavity sizes exceeding the one-third of the bucco-lingual distance between cusp tips -

Exclusion Criteria:

* Patients with periodontitis, poor oral hygiene, bruxism or a history of allergic reactions to any of the materials

Primary outcomes:
measure: Modified Ryge Criteria
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02556489: Transcriptomics Signature of Anti Vaccinia Memory B Cells
Official title: Transcriptomics Signature of Anti Vaccinia Memory B Cells in Healthy Individuals at a Short Time After Vaccination
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthy
Keywords: immunological memory
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2015-09-22
Enrollment: 12
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy donnors vaccinated against smallpox

Brief summary: Analyse the transcriptomic signature of anti vaccinia memory B cells at a short time after vaccination as compared to the signature already established in long-lived memory B cells.


Eligibility criteria: Inclusion Criteria:

* Healthy donors vaccinated against smallpox

Exclusion Criteria:

* none

Primary outcomes:
measure: signature of anti vaccinia long-lived memory B cells
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02009189: Taurolidine Lock in Long Term Parenteral Nutrition
Official title: The Value of Taurolidine Lock in Long Term Parenteral Nutrition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Home Parenteral Nutrition
Central Venous Catheter
Keywords: home parenteral nutrition
central venous catheter
Lead sponsor: Stanley Dudrick's Memorial Hospital
Sponsor class: OTHER
First posted: 2013-12-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: Taurolidine alone or in combination with citrate have been proposed for locking the catheter to reduce the number of catheter infections. As there is not enough evidence to give recommendations in this regard, the study tested the hipothesis that taurolidine improves the outcome of long term paretneral nutrition.


Eligibility criteria: Inclusion Criteria:

* home parenteral nutrition for at least months before enrollment
* presence of central venous cathter

Exclusion Criteria:

* home nutrition \< 12 months
* catheter in peripheral vein

Primary outcomes:
measure: Number of CVC infections
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Skawina
country: Poland
facility: Stanley Dudrick's Memorial Hospital
Study officials:
affiliation: Stanley Dudrick's Memorial Hospital
name: Stanislaw Klek, Assoc Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pittiruti M, Hamilton H, Biffi R, MacFie J, Pertkiewicz M; ESPEN. ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis and therapy of complications). Clin Nutr. 2009 Aug;28(4):365-77. doi: 10.1016/j.clnu.2009.03.015. Epub 2009 May 21.
Clinical trial NCT00282789: BiPAP for Cardiomyopathy With Central Sleep Apnea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dilated Cardiomyopathy
Lead sponsor: Nagoya University
Sponsor class: OTHER
First posted: 2006-01-27
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We investigated whether treatment of central sleep apnea-hypopnea with bilevel positive airway pressure (BiPAP) in patients with idiopathic dilated cardiomyopathy (IDCM) would improve LV function.


Eligibility criteria: Inclusion Criteria:

* Idiopathic dilated cardiomyopathy

Exclusion Criteria:

* a history of alcohol abuse, diabetes mellitus, endocrine disorders, hypertension, obstructive sleep apnea syndrome, and chronic obstructive pulmonary disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nagoya
country: Japan
facility: Nagoya University of Health Sciences
Study officials:
affiliation: Department of Cardiovascular Genome Science, Nagoya University School of Medicine, Nagoya, Aichi, Japan
name: Mitsuhiro Yokota, MD,PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01396889: Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years
Official title: Impact of Echinacea as Prophilaxis for Upper Respiratory Tract Infections in Children 1-5 Years in Bandarabbas Children' Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Upper Respiratory Tract Infections
Keywords: Upper Respiratory Tract Infections
Echinacea
viral infections
Lead sponsor: Hormozgan University of Medical Sciences
Sponsor class: OTHER
First posted: 2011-07-19
Enrollment: 100
Sex: ALL
Minimum age (years): 1
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Acute upper respiratory tract infections are the most commmon infections in children and are associated with complications such as acute otitis media, sinusitis and pneumonia. Echinacea is widely used for treatment of upper respiratoty tract infections. The aim of this study is to evaluate its efficacy as prophilaxis in children 1-5 years old.


Eligibility criteria: Inclusion Criteria:

* Childrens 1-5 years old

Exclusion Criteria:

* Wheezing in previous 3 months requiring bronchodilatator
* History of hyperactive reactive airway
* using steroid or Echinacea
* chronic pulmonary of cardiac disease
* Acute respiratory disease within one week before study
* Allergic rhinitis
* Allergy to Echinacea
* avoiding to participate in the study

Primary outcomes:
measure: occurrence of upper respiratory tract infection diagnosed by physician according to history and physical examination and laboratory tests if was necessary
timeFrame: 6 months
Secondary outcomes:
measure: Drug side effects
timeFrame: 6 months
Other outcomes:
Locations:
city: Bandar Abbas
country: Iran, Islamic Republic of
facility: Hormozgan University of Medical Sciences (HUMS)
state: Hormozgan
Study officials:
affiliation: Hormozgan University of Medical Sciences (HUMS)
name: Roya Firoozi, Resident
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02830789: Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass
Official title: Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass in Order to Treat Secondary Hyperparathyroidism: A Clinical Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Roux-en-Y Gastric Bypass
Hyperparathyroidism, Secondary
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2016-07-13
Enrollment: 38
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study investigates whether calcium citrate or calcium carbonate are the optimal supplement to treat secondary hyperparathyroidism following Roux-en-Y gastric bypass operation.

Half of the participants will be randomized to receive calcium citrate, while the other half will receive calcium carbonate. The study will be double blinded.


Eligibility criteria: Inclusion Criteria:

* Roux-en-Y gastric bypass operation ≥12 months ago
* Parathyroid hormone \> 6.9 pmol/l
* Vitamin D \> 50 nmol/l
* P-Calcium \[1.18-1.32\] mmol/l

Exclusion Criteria:

* Liver disease
* Renal disease
* Hypercalcemia
* Untreated thyroid disease
* Parathyroid disease except secondary hyperparathyroidism
* Use of diuretics, bisphosphonates, calcitonin, teriparatide, oral corticosteroids, anabolic steroids, calcimimetics, lithium, strontium, denosumab or anticonvulsants within 1 year of inclusion
* abusing alcohol

Primary outcomes:
measure: Parathyroid Hormone
timeFrame: Change from baseline at 6 weeks and 12 weeks
Secondary outcomes:
measure: Se-ion-calcium
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: P-magnesium
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: P-phosphate
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: P-25-OH-vitamin D
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: P-calcitriol
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: P-24,25-(OH)2-vitamin D
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: Vitamin D binding protein
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: Procollagen type 1 N-terminal propeptide (P1NP)
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: P-bone specific alkaline phosphatase
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: Cross-linked C-telopeptide (CTX)
timeFrame: Change from baseline at 6 weeks and 12 weeks
measure: 24h U-calcium
timeFrame: Change from baseline at 12 weeks
measure: 24h U-phosphate
timeFrame: Change from baseline at 12 weeks
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Enodocrinology and Internal Medicine, Aarhus University Hospital
Study officials:
References:
Clinical trial NCT01660789: "Fit For Kids"-Copenhagen
Official title: "Fit For Kids" Copenhagen - an Interventions Study on Obesity and Physical Inactivity in Children.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Obesity
Diabetes
Physical activity
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2012-08-09
Enrollment: 37
Sex: ALL
Minimum age (years): 7
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the effect of a 40- week multifactorial intervention against overweight, obesity and physical inactivity in Danish children.

The investigators wish to examine 40 children before and after the "Fit for Kids" intervention with basic anthropometric measures such as body mass indexi (BMI), waist/hip ratio, systolic- and diastolic blood pressure, level of physical fitness and Total Body fat mass.

Furthermore the investigators wish to examine the more specific inflammatory, metabolic and hormonal effect of the intervention with a more extensive examination programme.

The tests include a DXA-scan, cardio-respiratory fitness, accelerometer monitoring, pedometer monitoring, cognitive testing, Continuous Glucose Monitoring System, different metabolic and inflammatory markers and an oral glucose tolerance test. The study will take place at Centre of Inflammation and Metabolism, Rigshospitalet, Copenhagen.

The study is a randomised controlled trial with a gradual rollout. The 40 children will be randomised. Twenty children will start the intervention at baseline and 20 children will start after the first 20 weeks of intervention, thus providing a control group.

The investigators expect to find a significant reduction in BMI, total body fat mass and systolic blood pressure after the intervention. As for the more extensive tests, the data approach is explorative, as the investigators look at more statistical dependent variables. The contribution of this project is a further description on the effect of intervention against overweight and physical inactivity on the metabolic and inflammatory response.


Eligibility criteria: Inclusion Criteria:

* Obese children

Exclusion Criteria:

* Other chronic medical conditions
* Medical intake

Primary outcomes:
measure: BMI
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Centre of Inflammation and Metabolism, Rigshospitalet
Study officials:
affiliation: Centre of Inflammation and Metabolism
name: Nina Marie Birk Eriksen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Harder-Lauridsen NM, Birk NM, Ried-Larsen M, Juul A, Andersen LB, Pedersen BK, Krogh-Madsen R. A randomized controlled trial on a multicomponent intervention for overweight school-aged children - Copenhagen, Denmark. BMC Pediatr. 2014 Oct 21;14:273. doi: 10.1186/1471-2431-14-273.
Clinical trial NCT03030989: A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
Official title: A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Stem Cell Transplant Complications
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2017-01-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study evaluates the use of 2% CHG washcloths in an outpatient setting for adults after hematopoietic stem cell transplant in prevention of central line associated blood stream infections. Half of the participants will use 2% CHG washcloths and other half will use placebo washcloths.


Eligibility criteria: Inclusion Criteria:

* Admitted to the University of Chicago Hematopoietic Stem Cell Transplant Unit for transplant
* Age 18 and up

Exclusion Criteria:

* Experienced an allergy or rash related to use of chlorhexidine washcloths or other chlorhexidine products
* Extensive open wounds

Primary outcomes:
measure: Number of Participants With Primary Blood Stream Infections
timeFrame: 14 weeks
measure: Number of Participants With Clinical (Culture-negative) Sepsis
timeFrame: 14 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
References: